Gemilukast (ONO-6950) is primarily investigated for its potential therapeutic applications in treating respiratory conditions, particularly asthma and chronic obstructive pulmonary disease (COPD). It functions as a dual antagonist of cysteinyl leukotriene receptors (CysLT1 and CysLT2), which play a significant role in inflammation and bronchoconstriction associated with these diseases. By blocking these receptors, it helps reduce airway inflammation, improve lung function, and alleviate symptoms such as wheezing and shortness of breath. Its development is focused on offering an alternative or adjunctive treatment for patients who do not respond adequately to standard therapies like corticosteroids or beta-agonists. Research is ongoing to evaluate its efficacy and safety in clinical settings.